News Archive
The Ludwig Institute for Cancer Research (LICR) is an international non-profit research institute dedicated to improving the understanding and control of cancer. Below are highlights of the Institute’s news.
November 05, 2004
Lloyd J. Old, M.D. Receives Johns Hopkins University President’s Medal
LICR Director Dr. Lloyd J. Old was today awarded the Johns Hopkins University President’s Medal. The President’s Medal is an honor extended by the university to individuals who have achieved unusual distinction, and has been awarded to heads of state, members of Congress, a Supreme Court Justice, diplomats, literary figures, academics and other noteworthy individuals. In 2003, it was awarded to the USA’s Secretary of State, Colin Powell. First bestowed in 1978, the medal is awarded at the discretion of the President of the University.
October 17, 2004
International Ludwig Institute for Cancer Research Announces New Branch Director in London
The Ludwig Institute for Cancer Research (LICR) has appointed Professor Xin Lu as the new Director of the University College London (UCL) Branch of the LICR. Professor Lu was formerly a Group Leader at the LICR’s St Mary’s Branch, and studies the control of the key oncogene, p53.
August 21, 2004
Breakthrough in understanding of hereditary disease of lymphatic vessels
Researchers at the LICR Helsinki Affiliate Center have published, in Nature Medicine, the first study that describes a gene critical for the formation of lymphatic valves, and regulation of the interaction between lymphatic endothelial cells and vascular smooth muscle cells. The findings have implications for lymphedema therapies.
August 01, 2004
Another Key To The p53 Door
Researchers at the Uppsala Branch of the Ludwig Institute for Cancer Research have discovered that the transcription factor Yin Yang 1 (YY1) is a novel regulator of the p53 tumor suppressor p53, making YY1 a new target for future therapies.
July 19, 2004
Vaccine Target Boosts Immunity To Cancer
A therapeutic cancer vaccine being co-developed by the Ludwig Institute for Cancer Research (LICR) and the Australian biotechnology company CSL Limited successfully induced a comprehensive immune response in patients and appeared to delay cancer recurrence, according to a paper published today in the scientific journal, Proceedings of the National Academy of Sciences USA.
June 05, 2004
Melbourne Team Awarded US Grant To Lead International Cancer Trial
The Cancer Research Institute (CRI), one of the USA’s leading cancer charities, announced today that it has awarded 600,000 US Dollars (870,000 Australian Dollars) to the Joint Austin Health/Ludwig Institute for Cancer Research (LICR) Oncology Unit to lead an international Phase II clinical trial that will test the effectiveness of a therapeutic cancer vaccine for melanoma.
May 05, 2004
Second Generation Targeted Antibodies - It’s All in the Binding
Just weeks after one of the first anti-EGFR antibodies, ImClone’s Erbitux (Cetuximab), was approved for use in Europe and the USA, the unique binding properties of a ‘second generation’ anti-EGFR antibody from LICR have been elucidated. The antibody, 806, is able to discriminate between EGFR molecules on cancer cells and EGFR molecules on normal cells, and is set to enter early-phase clinical trials this year.
April 30, 2004
Setting the Gene Expression Base-line for Breast Cancer Research
In a paper published today in the journal Cancer Research a team of ICR and LICR scientists report that they have now elucidated the expression profiles of over 6000 genes in the two primary types of normal breast cells.
April 14, 2004
How Cancer Neutralizes T Cell Attack
New insights into how tumors neutralize CD8 T cells, and a strategy for overcoming the tumor’s response to attack.
March 14, 2004
Protein Sequences: Not So Predictable After All
A paper published in Science today by the Ludwig Institute for Cancer Research (LICR) describes a novel cellular process that casts some doubt on the accepted paradigm of deducing a protein’s sequence from the DNA sequence of its gene.
February 29, 2004
First Integrated Immunological Response — A Beacon For Cancer Vaccine Development
The Cancer Vaccine Collaborative, a partnership established by the Cancer Research Institute and the Ludwig Institute for Cancer Research, has today announced that it is the first to demonstrate that vaccination with a cancer-specific recombinant protein antigen has successfully induced a fully integrated immunological response in humans.
February 14, 2004
Molecular Classifiers For Potential New Prognosis of Gastric Cancer
Gastric cancer remains one of the major causes of cancer-related death worldwide, though it is eminently treatable if detected early. LICR investigators have now elucidated molecular classifiers that may improve the diagnosis and prognosis of gastric cancer.